124I-间碘苄胍：一种用于评估神经母细胞瘤的有前景的新型正电子发射放射性药物。
124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
作者信息
Cistaro Angelina, Quartuccio Natale, Caobelli Federico, Piccardo Arnoldo, Paratore Rosario, Coppolino Pietro, Sperandeo Alessandro, Arnone Gaspare, Ficola Umberto
机构信息
1. Positron Emission Tomography Centre IRMET S.p.A., Euromedic Inc., Turin, Italy 2. Coordinator of PET Pediatric AIMN InterGroup, Italy 3. Associate researcher of Institute of Cognitive Sciences and Technologies, National Research Council, Rome, Italy.
出版信息
Nucl Med Rev Cent East Eur. 2015;18(2):102-6. doi: 10.5603/NMR.2015.0024.
Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required.
神经母细胞瘤是儿科患者中最常见的颅外实体瘤。尽管123I-间碘苄胍（MIBG）和131I-MIBG闪烁扫描在该肿瘤中已确立作用，但关于124I-间碘苄胍（MIBG）正电子发射断层扫描（PET）/计算机断层扫描（CT）的应用数据有限。我们介绍了我们使用124I-MIBG PET/CT的初步经验：两名患有神经母细胞瘤的儿科患者接受了124I-MIBG PET/CT检查，以进行治疗前分布评估和再分期。我们旨在评估124I-MIBG PET/CT是否能比123I/131I-MIBG成像检测到更多的神经母细胞瘤病灶。我们的病例显示出有希望的结果，尽管124I-MIBG PET/CT还需要进一步验证和标准化。
Zotero 插件